ClinicalTrials.gg
CompletedNCT01254305Updated Aug 6, 2014Results posted

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

A Phase 2 interventional study of Levomilnacipran ER and Paroxetine, Sertraline, Citalopram or Fluoxetine. in Major Depressive Disorder, sponsored by Forest Laboratories. Completed at 20 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-08-06.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
262
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing levomilnacipran in Depressive Disorder, Major — none open to participants now, none under way, none of them phase 3. Levomilnacipran · Depressive Disorder, Major.

Enrollment
11th of 14
262 · median 472
Started
2011
with 1 other
Phase 2
Only one
of the 14
Registered
6th of 14
by date
Lead sponsor
9 of 14
Forest Laboratories

Among the 14 studies testing levomilnacipran in Depressive Disorder, Major, this one is the 11th largest by enrollment, is one of 2 that started in 2011, is the only one in phase 2, and was the 6th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

None of the 14 studies testing levomilnacipran in Depressive Disorder, Major is open now. The open studies under Depressive Disorder, Major, anywhere →

Where they have run

About levomilnacipran

Levomilnacipran: first FDA approval 2013 (FETZIMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing levomilnacipran in Depressive Disorder, Major as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy, safety and tolerability of Levomilnacipran ER for the treatment of fatigue associated with major depressive disorder (MDD).

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Depression
  • Fatigue
  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, 18-65 years old
  • Currently meet , Fourth Edition-Text Revision (DSM-IV-TR) criteria for Major Depressive Disorder
  • The patient's current depressive episode must be at least 4 weeks in duration

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, women who will be breastfeeding during the study, and women of who are not practicing a reliable method of
  • Patients with a history of meeting criteria for:

    1. any manic or hypomanic episode;
    2. schizophrenia or any other psychotic disorder;
    3. obsessive-compulsive disorder.
  • Patients who are considered a suicide risk
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
262 participants (actual)

Study arms

  • Experimental
    1

    40 -120 mg/day Levomilnacipran ER capsules, oral administration

    Drug: Levomilnacipran ER

  • Active comparator
    2

    Randomized to treatment with 1 of 4 Selective Serotonin Reuptake Inhibitors (SSRIs) - Paroxetine, Sertraline, Citalopram or Fluoxetine Oral administration, once daily dosing

    Drug: Paroxetine, Sertraline, Citalopram or Fluoxetine.

  • Placebo comparator
    3

    Matching placebo capsules, oral administration

    Drug: Placebo

Interventions

  • Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks

  • DrugParoxetine, Sertraline, Citalopram or Fluoxetine.

    Paroxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Sertraline (50, 100, or 150 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Citalopram (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks or Fluoxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks

  • DrugPlacebo

    Matching placebo capsules, oral administration, once daily dosing

06

What researchers measure

Primary outcomes

  1. Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score

    The CGI-S is a clinician-rated scale that rates the severity of the patient's current state of fatigue based on the Investigator's clinical opinion with regard to the patient population with Major Depressive Disorder (MDD). Patient were rated on a scale from 1 to 7, with 1 indicating a normal state and 7 indicating that the patient was among the most extremely fatigued

    Time frame: From Baseline to Week 8

  2. Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score

    The PGI-S is a clinician-rated scale that rates was used to rate the severity of the patient's current state of overall fatigue. Patients were rated on a scale from 1 to 7, with 1 indicating no symptoms of fatigue and 7 indicating extreme fatigue.

    Time frame: From Baseline to Week 8

Secondary outcomes

  1. Change in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward

    The Cognitive and Physical Functioning Questionnaire is a patient-rated, 7-item scale used to measure cognitive and executive dysfunction in mood and anxiety disorders. The CPFQ is sensitive to change with treatment and displays convergent validity by significant correlations with other measures of sleepiness, fatigue, apathy, and neuropsychological functioning. Patients are rated on a scale from 1 to 6 for seven common complaints of depressed patients reporting fatigue or cognitive/executive problems-with 1 indicating greater than normal functioning, 2 indicating normal functioning, and 3 to 6 indicating degrees of impaired functioning. The CPFQ ranges from the best possible score of 7 (greater than normal functioning) to the worst possible score of 42 (totally absent).

    Time frame: From Baseline to Week 8

07

Results

Posted Aug 6, 2014

Participant flow

Patients were recruited over a 12-month period from April of 2011 to April of 2012 at 20 studies sites in the United States.

Participant flow — Overall Study
MilestonePlaceboLevomilnacipran ERSSRI
Started939079
Safety population898577
Completed717262
Not completed221817
Withdrew: Adverse event632
Withdrew: Lack of efficacy101
Withdrew: Protocol violation173
Withdrew: Withdrawal by subject424
Withdrew: Lost to follow-up1065
Withdrew: Other reasons002

Outcome measures

PrimaryChange in Clinical Global Impression of Severity (CGI-S) for Fatigue Score

The CGI-S is a clinician-rated scale that rates the severity of the patient's current state of fatigue based on the Investigator's clinical opinion with regard to the patient population with Major Depressive Disorder (MDD). Patient were rated on a scale from 1 to 7, with 1 indicating a normal state and 7 indicating that the patient was among the most extremely fatigued

Time frame:
From Baseline to Week 8
Reported as:
Mean · units on a scale
Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score
units on a scalePlaceboLevomilnacipran ERSSRI
Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score-1.5 ± 1.3-1.8 ± 1.4-1.9 ± 1.4
SecondaryChange in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward

The Cognitive and Physical Functioning Questionnaire is a patient-rated, 7-item scale used to measure cognitive and executive dysfunction in mood and anxiety disorders. The CPFQ is sensitive to change with treatment and displays convergent validity by significant correlations with other measures of sleepiness, fatigue, apathy, and neuropsychological functioning. Patients are rated on a scale from 1 to 6 for seven common complaints of depressed patients reporting fatigue or cognitive/executive problems-with 1 indicating greater than normal functioning, 2 indicating normal functioning, and 3 to 6 indicating degrees of impaired functioning. The CPFQ ranges from the best possible score of 7 (greater than normal functioning) to the worst possible score of 42 (totally absent).

Time frame:
From Baseline to Week 8
Reported as:
Mean · units on a scale
Change in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward
units on a scalePlaceboLevomilnacipran ERSSRI
Change in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward-5.9 ± 7.9-7.0 ± 7.3-6.4 ± 7.0
PrimaryChange in Patient Global Impressions of Severity (PGI-S) for Fatigue Score

The PGI-S is a clinician-rated scale that rates was used to rate the severity of the patient's current state of overall fatigue. Patients were rated on a scale from 1 to 7, with 1 indicating no symptoms of fatigue and 7 indicating extreme fatigue.

Time frame:
From Baseline to Week 8
Reported as:
Mean · units on a scale
Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score
units on a scalePlaceboLevomilnacipran ERSSRI
Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score-1.4 ± 1.5-1.7 ± 1.5-1.7 ± 1.5

Adverse events

Collected over Adverse event data occurred over a 16-month period from April of 2011 to September of 2012 at 20 studies sites in the United States.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/89 (0%)39/89 (43.8%)
Levomilnacipran ER—1/85 (1.2%)41/85 (48.2%)
SSRI—0/77 (0%)37/77 (48.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboLevomilnacipran ERSSRI
PneumoniaInfections and infestations0/891/850/77
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlaceboLevomilnacipran ERSSRI
NauseaGeneral disorders4/8914/856/77
HeadacheNervous system disorders14/8912/856/77
Dry mouthGastrointestinal disorders6/898/859/77
DiarrhoeaGastrointestinal disorders8/894/859/77
Upper respiratory tract infectionInfections and infestations7/890/853/77
SomnolenceNervous system disorders4/893/856/77
DizzinessNervous system disorders2/896/851/77
Heart rate increasedInvestigations3/896/850/77
InsomniaPsychiatric disorders1/892/855/77
AnxietyPsychiatric disorders1/891/855/77

Baseline characteristics

A total of 262 patients were randomized to receive double-blind treatment. The Baseline Participant population is based on the 251 randomized patients received at least 1 dose of double-blind treatment (Safety Population).

Age, Continuous
Age, Continuous(years)PlaceboLevomilnacipran ERSSRITotal
Mean41.4 ± 12.042.9 ± 12.642.8 ± 11.342.3 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLevomilnacipran ERSSRITotal
Female584949156
Male31362895
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboLevomilnacipran ERSSRITotal
White625747166
Black or African American26252576
Asian1326
American Indian or Alaska Native0011
Native Hawaiian or Other Pacific Islander0000
Other0022
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboLevomilnacipran ERSSRITotal
Hispanic or Latino841022
Not Hispanic or Latino818167229
Region of Enrollment
Region of Enrollment(participants)PlaceboLevomilnacipran ERSSRITotal
United States898577251
Weight
Weight(kg)PlaceboLevomilnacipran ERSSRITotal
Mean79.95 ± 15.2782.23 ± 18.1483.31 ± 17.6181.75 ± 17.00
Body Mass Index (BMI)
Body Mass Index (BMI)(Kilograms Per Meter Squared)PlaceboLevomilnacipran ERSSRITotal
Mean28.16 ± 4.8528.61 ± 5.2228.80 ± 5.1028.51 ± 5.04
08

Study locations

20 sites
  • Forest Investigative Site 010
    Birmingham, Alabama 35216, United States
  • Forest Investigative Site 002
    Little Rock, Arkansas 72223, United States
  • Forest Investigative Site 001
    Cerritos, California 90703, United States
  • Forest Investigative Site 014
    Fort Myers, Florida 33912, United States
  • Forest Investigative Site 006
    Jacksonville, Florida 32216, United States
  • Forest Investigative Site 017
    Orange City, Florida 32763, United States
  • Forest Investigative Site 005
    Orlando, Florida 32806, United States
  • Forest Investigative Site 012
    Tampa, Florida 33613, United States
  • Forest Investigative Site 009
    Atlanta, Georgia 30308, United States
  • Forest Investigative Site 016
    Joliet, Illinois 60435, United States
  • Forest Investigative Site 004
    New Orleans, Louisiana 70122, United States
  • Forest Investigative Site 022
    Boston, Massachusetts 02135, United States
  • Forest Investigative Site 011
    Bronx, New York 10467, United States
  • Forest Investigative Site 015
    Cedarhurst, New York 11516, United States
  • Forest Investigative Site 003
    Cincinnati, Ohio 45227, United States
  • Forest Investigative Site 013
    Dayton, Ohio 45417, United States
  • Forest Investigative Site 020
    Lincoln, Rhode Island 02865, United States
  • Forest Investigative Site 018
    Memphis, Tennessee 38119, United States
  • Forest Investigative Site 008
    Dallas, Texas 75235, United States
  • Forest Investigative Site 007
    Middleton, Wisconsin 53562, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 2 years 1 month after primary completion. A results delay was requested in Jul 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2010
First posted
Dec 6, 2010
Start
Apr 2011
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results delay requested
Jul 25, 2012
Results first posted
Aug 6, 2014
Last update
Aug 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01254305
Responsible party
Sponsor
First posted
Dec 6, 2010
Start date
Apr 2011
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Aug 6, 2014
Last update
Aug 6, 2014

Study contacts

Carl Gommoll, MS
study director · Forest Laboratories

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levomilnacipran

Start the discussion